POTENTIATION OF THE CYTOTOXIC ACTIVITY OF MELOXICAM AGAINST COX-2 NEGATIVE COLON CANCER CELLS BY NANOPARTICULATE ENCAPSULATION
Areeg Awadallah1, Rawan Al-Karaki1, Maha Nasr2*
1. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Mutah University, Jordan 2. Department of Pharmaceutics and Industrial pharmacy , Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
Keywords: Meloxicam, nanoemulsion, colon cancer, HCT-116 cells, COX-2.
Abstract

Objective: The aim of the current work was to elucidate whether the nanoencapsulation of meloxicam would allow its exertion of anticancer activity on colon cancer cells despite lacking COX-2 expression. Methods: Meloxicam nanoemulsion was prepared using the water dilution method, in which oleic acid was chosen as the oily phase, tween 20 as surfactant and ethanol as cosurfactant. The nanoemulsion was characterized in terms of particle size, zeta potential, polydispersity index, morphology, in vitro drug release, stability and anticancer activity on HCT-116 colon cancer cells. Results: It was shown that meloxicam nanoemulsion was successfully prepared with a particle size of 11 nm, polydispersity index of 0.278 and a neutral charge, and it was able to sustain the release of drug for 24 hours with a cumulative percent released of 86%. Its spherical morphology was confirmed using transmission microscopy. No significant changes in particle size, polydispersity or charge were observed upon storage, suggesting the stability of the nanosystem. Moreover, the nanoemulsion exhibit significant cytotoxicity on HCT-116 compared to non-encapsulated meloxicam, suggesting that the prepared nanoemulsion was a successful delivery carrier for meloxicam, which is capable of potentiating its anticancer activity in a non COX-2 dependant manner.

Article Information

Identifiers and Pagination:
Year:2019
Volume:11
First Page:9
Last Page:17
Publisher Id:JAppPharm (2019 ). 11. 9-17
Article History:
Received:March 10, 2019
Accepted:May 17, 2019
Collection year:2019
First Published:May 20, 2019


© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany

Bibliography

Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885
office@consortiumpublisher.ca
http://www.consortiumpublisher.ca/